 Home > Medical News > Medicines Company News > Nuocheng Jianhua will announce the clinical data of the pan-FGFR inhibitor gunagratinib at the annual meeting of the American Society of Clinical Oncology in 2021

Nuocheng Jianhua will announce the clinical data of the pan-FGFR inhibitor gunagratinib at the annual meeting of the American Society of Clinical Oncology in 2021

 Last Update: 2021-07-06
 Source: Internet
 Author: User

Tags

annual reports 2018

benicar drug class

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Biomedical high-tech company Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) today announced that the company's pan-FGFR inhibitor gunagratinib (ICP-192) clinical data will be announced at the 2021 American Society of Clinical Oncology (ASCO) annual meeting , And was selected to be displayed in the form of a poster.
This is also the first time that gunagratinib has presented clinical data at an international academic conference.
The abstract will be published on ASCO's official website on May 19th, US time
.

The 2021 ASCO Annual Meeting will be held online from June 4 to 8, 2021
.
The ASCO annual meeting is the most important and authoritative academic exchange event in the global oncology field, which will showcase the current international cutting-edge clinical oncology scientific research results and tumor treatment technologies

Nuocheng Jianhua will present the latest clinical progress of gunagratinib at the ASCO annual meeting
.
ICP-192 is a class 1 innovative drug with global independent intellectual property rights under Nuocheng Jianhua.

It is a small molecule pan-FGFR inhibitor that can be used to treat a variety of solid tumors and is highly selective.

Selected study: Phase I clinical results of a highly selective irreversible FGFR inhibitor ICP-192 (gunagratinib) for patients with advanced solid tumors with abnormal FGFR genes

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Nuocheng Jianhua announced the latest clinical data of the pan-FGFR inhibitor gunagratinib at the 2021 American Society of Clinical Oncology (ASCO) annual meeting

06-30

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Nuocheng Jianhua will announce the clinical data of the pan-FGFR inhibitor gunagratinib at the annual meeting of the American Society of Clinical Oncology in 2021

Related Articles

Nuocheng Jianhua announced the latest clinical data of the pan-FGFR inhibitor gunagratinib at the 2021 American Society of Clinical Oncology (ASCO) annual meeting